Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).…
European Medicines Agency Validates Type II Variation Application for PADCEV® with KEYTRUDA® for First-Line Treatment of Advanced Bladder Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review a…
Merck’s KEYTRUDA® Significantly Improved Disease-Free Survival as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the…
AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more…
Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024
Allergan Aesthetics, the industry leader in aesthetics globally, continues to bring best-in-class programming highlighting Individuality, Innovation, and Integrity at the International Master Course on Aging Science (IMCAS) World Congress 2024…
Application for regulatory approval of Aflibercept 8 mg accepted in China
Bayer today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) accepted the submission of an application for regulatory approval of aflibercept 8 mg…
Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals Division
Bayer today announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the…
TOP 40 HIGH SCHOOL SCIENTISTS IN PRESTIGIOUS REGENERON SCIENCE TALENT SEARCH TO COMPETE FOR $1.8 MILLION IN AWARDS
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search, the nation’s oldest and most prestigious science and math competition for high…
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on…
Opdivo® in Combination with CABOMETYX® Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced four-year follow-up results from the CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) vs. sunitinib in patients with previously untreated advanced…
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which…
Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of…